An Extension Study to Assess Impact of Multiple Sclerosis (MS) on Physical Function and Provide Continued Ocrelizumab Treatment

Recruiting

Phase 3 — Large-scale testing across thousands of people, comparing the new treatment against current standard treatments.

Trial locations(44 sites)

France

CHU Amiens Hopital Sud, Amiens Cedex1

CHU de Besancon Hopital Jean Minjoz, Besançon

Groupe Hospitalier Pellegrin, Bordeaux

CHU Brest Hopital La Cavale Blanche, Brest

Hopital neurologique Pierre Wertheimer - CHU Lyon, Bron